Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary
Avai Bio reported no revenue for 3Q 2026, with a net loss of $253,240, a 44% improvement from the prior year. Operating expenses decreased 36% and other expenses fell to zero. The company acquired the Lifestyle Wellness Assessment API for $58,600. Operating cash use declined $122,313 year over year to $489,577 in the six months ended September 30, 2026.
How this was made

The 30-second read
Why it matters
The filing provides the first public numbers for Q3 2026, showing zero revenue and a narrowed net loss, which may modestly affect the stock price.
Market read
Micro‑cap earnings with loss improvement; limited but potentially actionable for short‑term traders.
What to watch
The acquisition of a wellness API could signal a strategic pivot that the market has not fully priced in.
Background
Avai Bio is a clinical‑stage biotech focused on metabolic disorders. The 10‑Q reflects ongoing cost reductions and a recent API acquisition.
Ticker impact
Avai Bio filed its 10‑Q showing zero revenue and a narrowed net loss for Q3 2026.
likely slight upward pressure as the market prices in improved loss profile
Micro‑cap earnings with loss improvement often lead to modest price gains, but limited scale keeps impact small.
Market effects
Minimal impact on the broader biotech sector; results reflect company‑specific challenges.
Limited to US micro‑cap investors; no broader regional effect.
Low global relevance given the company's size and niche focus.
Counterpoint
Investors may view the loss narrowing as insufficient without revenue growth, maintaining a bearish stance.
Key entities
- companyAvai Bio, Inc.
Biotech firm reporting its Q3 2026 10‑Q results.
